Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
11,933,401
-
Share change
-
+125,477
-
Total reported value
-
$102,508,360
-
Price per share
-
$8.59
-
Number of holders
-
67
-
Value change
-
-$12,039,057
-
Number of buys
-
47
-
Number of sells
-
28
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2018
As of 31 Mar 2018,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,933,401 shares.
The largest 10 holders included
FMR LLC, EcoR1 Capital, LLC, FARALLON CAPITAL MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Pharmstandard International S.A., BlackRock Inc., VANGUARD GROUP INC, BVF INC/IL, Cormorant Asset Management, LP, and MILLENNIUM MANAGEMENT LLC.
This page lists
67
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.